UNC is now a fully active clinical site for the ACTIV-4c Post-Hospital Thrombosis Prevention Study. This protocol is part of the larger ACTIV (Accelerating COVID-Therapeutic Interventions and Vaccine) study. This protocol focuses on preventing blood clots in patients discharged after being hospitalized with COVID-19. UNC is now enrolling participants in this adaptive, prospective, randomized, double-blinded trial to evaluation the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge.
The UNC ACTIV-4c Team is led by the site Principal Investigator, Raj Kasthuri, MBBS, professor of medicine in the division of hematology. Other UNC faculty include, Nigel Key, MD, the Harold R. Roberts Distinguished Professor of Medicine, Stephan Moll, MD, professor of medicine, Micah Mooberry, MD, assistant professor of medicine, and Yasmina Abajas, MD, assistant professor of pediatrics. The study team also includes staff in the UNC Blood Research Center, Brett Phillips, Laura Finerty, Amy Brightwood, and Kelly Kivette.
Read more from the UNC Health and UNC School of Medicine Newsroom.